Literature DB >> 3860629

Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia.

R J Wells, J Feusner, R Devney, W G Woods, A J Provisor, M S Cairo, L F Odom, J Nachman, G R Jones, L J Ettinger.   

Abstract

Sequential high-dose cytosine arabinoside (ara-C) and asparaginase were given to 41 children age six months to 21 years of age with advanced leukemia. Ten of 22 patients with acute lymphocytic leukemia (ALL) and eight of 19 patients with acute nonlymphocytic leukemia (ANLL) obtained complete remissions. The most significant toxicity seen was infection in 22 patients. In addition, patients given intrathecal chemotherapy within 24 hours of ara-C developed neurologic toxicity. The high response rate seen in these patients with advanced leukemia indicates that a trial of this regimen is warranted in children with less advanced ALL and ANLL.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3860629     DOI： 10.1200/JCO.1985.3.7.998

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  11 in total

1.  Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.

Authors:  Richard L Tower; Tamekia L Jones; Bruce M Camitta; Barbara L Asselin; Beverly A Bell; Allen Chauvenet; Meenakshi Devidas; Edward C Halperin; Jeanette Pullen; Jonathan J Shuster; Naomi Winick; Joanne Kurtzberg
Journal:  J Pediatr Hematol Oncol       Date:  2014-07       Impact factor: 1.289

Review 2.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

3.  Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.

Authors:  Ronald Dubowy; Michael Graham; Nasrollah Hakami; Morris Kletzel; Donald Mahoney; Edward Newman; Yaddanapudi Ravindranath; Bruce Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2008-05       Impact factor: 1.289

4.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  K Nguyen; M Devidas; S-C Cheng; M La; E A Raetz; W L Carroll; N J Winick; S P Hunger; P S Gaynon; M L Loh
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

5.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

Authors:  Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

6.  Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin.

Authors:  H F Guiot; W G Peters; P J van den Broek; J W van der Meer; J A Kramps; R Willemze; R van Furth
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

7.  Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood--follow up after 9 years. Coall Study Group.

Authors:  G E Janka-Schaub; D Harms; U Goebel; U Graubner; P Gutjahr; R J Haas; H Juergens; H J Spaar; K Winkler
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

8.  Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].

Authors:  Elizabeth A Raetz; Michael J Borowitz; Meenakshi Devidas; Stephen B Linda; Stephen P Hunger; Naomi J Winick; Bruce M Camitta; Paul S Gaynon; William L Carroll
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

9.  Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

Authors:  Catriona Parker; Rachel Waters; Carly Leighton; Jeremy Hancock; Rosemary Sutton; Anthony V Moorman; Philip Ancliff; Mary Morgan; Ashish Masurekar; Nicholas Goulden; Nina Green; Tamas Révész; Philip Darbyshire; Sharon Love; Vaskar Saha
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

10.  The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.

Authors:  A Masurekar; C Fong; A Hussein; T Revesz; P M Hoogerbrugge; S Love; C Ciria; C Parker; S Krishnan; V Saha
Journal:  Blood Cancer J       Date:  2014-04-25       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.